🇺🇸 FDA
Patent

US 8815511

Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate

granted A61KA61K38/02A61K38/16

Quick answer

US patent 8815511 (Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K38/02, A61K38/16, A61K45/06, A61P